Pharmaceutical companies, on June 29th, will face tougher price scrutiny and the risk of being expelled from the pharmaceutical market, as they bid up the price of medicines and raw materials.
▍ bid up the price serious: ejected from the medical market
Yesterday (28), the state development planning commission, the national development and reform commission, the ministry, the ministry of finance, people club department, the ministry of commerce, state-owned assets supervision and administration commission of the state council, state administration for industry and commerce, the national food administration of drug safety and other nine departments jointly issued "on the reform to perfect the shortage of drug supply security mechanism of the implementation opinions" (countries who medicine ZhengFa [2017] no. 37) (hereinafter referred to as "implementation opinion"), announced that nine departments joint management shortage of medicine in a series of measures.
Cracking down on illegal price gouging is an important part of the New Deal.
According to "implementation opinion", nine departments will strengthen the API source, business inventories and market transaction behavior, such as monitoring, comprehensive assessments MiaoTouXing issues and trends, the price rise significantly in the production of active pharmaceutical ingredients and drug distribution enterprises pay close attention to, when it is necessary to carry out special investigation cost price. We will strengthen the supervision of drugs and the market for raw materials, and investigate and punish illegal and illegal activities such as price and monopoly in accordance with the law, and increase penalties and maintain market order.
Not only that, according to the file open information yesterday, the shortage of pharmaceuticals monopoly API price behavior guide is also formulate - "build system of faithless operator blacklist, the shortage of repeatedly check and make active pharmaceutical ingredients and drug products is relevant to the monopoly operator, in accordance with the prohibition against the measures in the drug industry. Strictly carry out drug purchase credit records and repel the market system."
Frequently reported in recent years shows that, in fact, many drug shortages occur, because the monopoly operator in the economic interests of the driven "up for grabs," this kind of phenomenon more and more obvious in the field of upstream API production.
, deputy director of the national health development planning commission yi-xin zeng yesterday also said that in the scio release drug shortages complex causes, in addition to the productive factors, imperfect supporting policies, public hospitals use enthusiasm is not high factors, individual drug control of raw materials, stock up not to sell, raise prices, the market supply tension, speculative monopoly factors have caused the current part of the drug shortage situation.
▍ shortage of 130 kinds of medicine, 50 have been solved
According to public information display in health development planning commission yesterday, has combed out the list of clinical easy shortage of about 130, including nearly 50 kinds of listing in drug shortage has been through the designated production, coordination of emergency production, strengthening the supply and demand docking, shortage of perfect pharmaceutical reserve, to crack down on illegal behavior, improve the rare disease medication six countermeasures such as policy is solved.
In the next step, the management system for the list of shortage medicines will be implemented, and the management system for the list of shortages of medicines in countries and provinces will be established. According to the situation of shortage, shortage and scope of influence, timely launch the national or provincial response mechanism, publish relevant information regularly, and realize the dynamic management of shortage drug inventory.
The paper gives a clear answer to the question of the pricing of general concern to the enterprise.
Shortages of drugs are being implemented at designated points. Comprehensive clinical required, small dosage or market price is low and the shortage of power enterprise production factors, selecting the fixed-point production varieties, through the government pricing, price negotiations, market set a variety of ways, such as to determine the unified purchase price, reasonable supply security area, bidding to determine fixed-point production enterprise, the net purchase directly.
The health and family planning commission released yesterday's interpretation of the implementation opinion, which has made companies not worried about profits and development.
"Shortage of drugs is most necessary clinical, small dosage or market price is low, less profit, the production of steam." opinions "clearly put forward by designated production, optimizing the mechanism of drug purchase, determine a reasonable purchase price, making market transaction price forming mechanism, support enterprises technology upgrade, improve the shortage of pharmaceutical reserve, gives the reasonable profits, solve the problem of structural imbalances, stimulates the market vitality, productivity development space."
, yi-xin zeng also revealed yesterday that "(pressure too low cost) is one reason for the shortage of drugs, some media called 'tender death, after the bid is winning death, is the bid, pharmaceutical factory also agreed, but after a period of time after the drug had disappeared. We should respect the market rule, can't let companies lose money supply for a long time, this situation requires the government to coordinate, ask an expert to analyze, to pharmaceutical raw material supply, production process, production process were analyzed, and put forward a more appropriate price. The market principle reflected in the basic premise, respect the will of both sides of supply and demand, on the basis of through the government's coordination mechanism, to more drug supplies back to stable state. It is also an important task of" opinion "issued, is to begin to address this issue." |
